Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 AUD | 0.00% | -9.09% | -59.46% |
May. 08 | Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities | MT |
Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Sales 2024 * | 64.48K 96.85K | Sales 2025 * | - | Capitalization | 9.17M 13.77M |
---|---|---|---|---|---|
Net income 2024 * | -29M -43.56M | Net income 2025 * | -31M -46.56M | EV / Sales 2024 * | 224 x |
Net Debt 2024 * | 5.28M 7.93M | Net Debt 2025 * | 3.96M 5.94M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.29
x | P/E ratio 2025 * |
-0.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.25% |
1 week | -9.09% | ||
Current month | -6.25% | ||
1 month | -26.83% | ||
3 months | -53.12% | ||
6 months | -60.00% | ||
Current year | -59.46% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-09-12 | |
Antje Wegener
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gitasha Chand
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Hopper
CHM | Chairman | 68 | 21-02-10 |
Leila Alland
BRD | Director/Board Member | 61 | 22-06-05 |
Chief Executive Officer | - | 21-09-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 0.03 | 0.00% | 713 211 |
24-06-05 | 0.03 | +11.11% | 971,116 |
24-06-04 | 0.027 | -10.00% | 2,167,502 |
24-06-03 | 0.03 | -6.25% | 629,356 |
24-05-31 | 0.032 | -3.03% | 345,802 |
Delayed Quote Australian S.E., June 06, 2024 at 01:29 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-59.46% | 9.17M | |
+42.69% | 749B | |
+34.11% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+18.08% | 248B | |
-3.44% | 214B | |
+11.35% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- RAD Stock